Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

GALT Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Galectin Therapeutics Inc.NASDAQ: GALT

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 3.2% from a year ago

Common stock stood at $65K at the end of Q1 FY2026, up 3.2% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Common stock amounted to 0.4% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +3.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$65K+0.0% QoQ
Last fiscal yearDec 2025
$65K+4.8% YoY
Year agoMar 2025
$63K+3.2% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.2%——
1 year+4.8%——
3-year CAGR+3.3%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
65K USD
Year-over-year change
+4.8%
4-year CAGR
+2.5%

Common Stock vs competitors

How GALT compares with its peers on the latest reported figures

  • GALT's Mar 2026 common stock of $65K is the 3rd highest of the 10 companies compared; the peer median is $6K.
  • Its year-over-year change of +3.2% is the 5th highest of 7, against a peer median of +23.1%.
  • Common stock amounts to 0.4% of total assets for GALT, versus a peer median of 0.0%.
GALT Competitors Peer median
Common Stock for GALT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENGNenGene Holdings Inc.Apr 2026$632M +23.9%+57.4%205.5%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$1.09M +2.2%+11.0%0.4%
GALTGalectin Therapeutics Inc.Mar 2026$65K +3.2%+3.3%0.4%
QSIQuantum-Si incorporatedMar 2026$22K +22.2%+16.3%0.0%
ALTAltimmune, Inc.Mar 2026$13K +62.5%+30.1%0.0%
DSGNDesign Therapeutics, Inc.Mar 2026$6K +0.0%+0.0%0.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$3K +200.0%+44.2%0.0%
DRTSAlpha Tau Medical Ltd.Mar 2026$0 ——0.0%
AURAAura Biosciences, Inc.Mar 2026$0 ——0.0%
DMACDiaMedica Therapeutics Inc.Mar 2026$0 ——0.0%
Peer median (excluding GALT) $6K+23.1%+23.2%0.0%

Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents39.65M18.59M25.66M15.12M17.72M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets2.17M1.96M2.05M2.13M1.72M
Total Current Assets41.82M20.55M27.71M17.25M19.44M
Property, Plant & Equipment (Net)0053K00
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets7K733K437K243K96K
Total Non-current Assets7K733K490K243K96K
Total Assets41.83M21.29M28.2M17.5M19.53M
Account Payables1.81M3.89M6.43M5.66M3.25M
Short-term Debt00021.12M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.49M8.11M8.07M1.89M1.06M
Total Current Liabilities9.03M13.01M15.68M35.41M8.03M
Long-term Debt29.05M39.83M71.74M85.11M133.74M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.13M639K1M47K3.96M
Total Non-current Liabilities30.18M40.47M72.77M85.16M137.7M
Total Liabilities39.21M53.48M88.44M120.57M145.73M
Common Stock59K59K61K62K65K
Retained Earnings(270.69M)(309.57M)(354.37M)(401.57M)(432.55M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity2.62M(32.19M)(60.24M)(103.07M)(126.2M)
Total Debt29.06M39.87M71.81M106.25M133.76M
Net Debt(10.59M)21.28M46.15M91.13M116.04M

Galectin Therapeutics Inc.

NASDAQ:GALT

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.